PR Newswire Clinical TrialsOriginal article
European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
RegulatoryasedebartPositive
AI Analysis
Summary
The European Commission granted orphan designation for Lundbeck's asedebart (Lu AG13909), an investigational anti-ACTH monoclonal antibody, for treating Cushing's syndrome of endogenous origin, a rare endocrine disorder.
Outcome Details
European Commission granted orphan designation
Importance:6/10
Sentiment:
0.70
orphan designationmonoclonal antibodyanti-ACTHrare diseaseendocrine disorderEuropean Commission
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 24, 2026 9:35 AM